logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Cost of relapse in schizophrenia.

    Article - En anglais

    Fulltext.

    To estimate the national annual cost of rehospitalization for multiple-episode schizophrenia outpatients, and to determine the relative cost burden from loss of medication efficacy and from medication noncompliance, the yearly number of neuroleptic-responsive multiple-episode schizophrenia inpatients in the United States who are discharged back to outpatient treatment was estimated.

    The cohort at risk for future relapse and rehospitalization was determined.

    The monthly relapse rates are estimated to be 3.5 percent per month for patients on maintenance neuroleptics and 11.0 percent per month for patients who have discontinued their medication.

    Postdischarge noncompliance rates in community settings are estimated to be 7.6 percent per month.

    Within 2 years after discharge, the aggregate cost of readmission approached $2 billion.

    Loss of neuroleptic efficacy accounted for roughly 60 percent of the rehospitalization costs and neuroleptic noncompliance for roughly 40 percent.

    The economic burden due to loss of efficacy is relatively higher during the first postdischarge year, whereas the burden from noncompliance is higher in the second year.

    Because loss of medication efficacy and medication noncompliance act synergistically on relapse, substantial inpatient cost savings can be realized by linking better pharmacologic treatments of schizophrenia with more effective strategies to manage medication noncompliance.

    Mots-clés Pascal : Schizophrénie, Psychose, Chimiothérapie, Psychotrope, Neuroleptique, Efficacité traitement, Observance médicamenteuse, Récidive, Hospitalisation, Analyse coût, Economie santé, Santé mentale, Etats Unis, Amérique du Nord, Amérique, Homme

    Mots-clés Pascal anglais : Schizophrenia, Psychosis, Chemotherapy, Psychotropic, Neuroleptic, Treatment efficiency, Drug compliance, Relapse, Hospitalization, Cost analysis, Health economy, Mental health, United States, North America, America, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0489602

    Code Inist : 002B18H05B. Création : 01/03/1996.